SCHEMBL10243651

SCHEMBL10243651

CCN(CCNC(=O)OC)C(C)c1cccn1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
PGR P06401 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
HTR2A P28223 1/20 0.34
HRH1 P35367 1/20 0.34
KCNH2 Q12809 1/20 0.34
KDM4E B2RXH2 1/20 0.33
P4HB P07237 1/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
CYP2D6 P10635 2/20 0.32
KCNA5 P22460 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MTNR1A P48039 3/20 0.32
MTNR1B P49286 3/20 0.32
EPHX1 P07099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243497 0.81 SLC22A1 (0.43) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL10243567 0.80 TAS1R3 (0.34) PGRKDM4ECYP2D6KCNA5L3MBTL1
SCHEMBL10243630 0.78 EPHX1 (0.31) TSHRCYP2D6SMN1; SMN2MTNR1AMTNR1B
SCHEMBL10243922 0.76 RAB9A (0.35) RAB9ANPC1PGRADRA2AADRA2B
SCHEMBL10243931 0.76 CYP2D6 (0.33) CYP2D6ALDH1A1SMN1; SMN2HPGDCYP1A2
SCHEMBL10243520 0.76 RAB9A (0.38) RAB9ANPC1TSHRKCNA5ALDH1A1
SCHEMBL10243634 0.75 TSHR (0.40) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL10243454 0.75 KDM4E (0.37) PGRADRA2AADRA2BHTR2AHRH1
SCHEMBL10243117 0.75 L3MBTL1 (0.41) TSHRHTTL3MBTL1ALDH1A1MTNR1A
SCHEMBL10243510 0.74 ALOX5 (0.40) L3MBTL1ALDH1A1SMN1; SMN2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 RAB9A 5/4885NPC1 209/4885PGR 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.